Northwestern University Feinberg School of Medicine

Parkinson's Disease and Movement Disorders Center

(CTH-300) A Phase 3 Study to Examine the Efficacy, Safety and Tolerability of APL-130277

Study Title: (CTH-300) A Phase 3 Study to Examine the Efficacy, Safety and Tolerability of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease

ClinicalTrails.gove Identified:  NCT02469090

Clinical Trial Investigator:  Cindy Zadikoff, MD

A 12-week prospective, multi-center, randomized, double-blind, placebo controlled, Phase 3 study in L-Dopa responsive PD patients with motor fluctuations ("off" episodes), designed to determine the efficacy, safety and tolerability of APL=130277 (sublingual apomorphine thin films).  Patients who complete the study will be eligible for the 24 week Open Label study (CTH-301) to determine the long-term safety, tolerability, and efficacy of APL-130277.

Clinical Trial Eligibility Criteria:

Study Visits: 13 Clinic Visits & 4 telephone follow-ups (over 12 wks)

Treatment:  APL-130277 (sublingual apomorphine thin films) or Placebo

Compensation: $50 for each visit

IRB#: Project: STU00201467

For More Information: Call us at 312-503-0755, or email pdclinicaltrials@northwestern.edu.